|会社名||Myovant Sciences Ltd （MYOVANT SCIENCES）|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||Myovant Sciences Ltd is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment women’s health and endocrine diseases. Its lead product candidate is Relugolix which is an oral once-daily small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is also advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids endometriosis-associated pain and advanced prostate cancer. The Company is developing MVT-602 an oligopeptide kisspeptin agonist for the treatment of female infertility. マイオバント・サイエンシズはバミュ―ダ諸島籍のバイオ医薬品企業。臨床段階で、主に女性特有の疾患と前立腺がんに対する治療薬の開発・商業化に従事する。同社パイプライン「Relugolix」は子宮筋腫、子宮内膜症、前立腺がんを治療する経口薬。また、「RVT-602」は女性の不妊症治療に利用される。本社はハミルトン。 Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.|
|本社所在地||Suite 1 3rd Floor 11-12 St. James's Square London SW1Y 4LB GBR|
|代表者氏名||Myrtle Stephens Potter|
|代表者役職名||Chairman of the Board|
|決算概要||BRIEF: For the nine months ended 31 December 2018 Myovant Sciences Ltd revenues was not reported. Net loss increased from $95M to $198.5M. Higher net loss reflects Research and development - Balancing increase from $74M to $158.3M (expense) General and administrative - Balancing increase of 87% to $21.2M (expense) Interest expense increase from $904K to $4.8M (expense).|
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis 2021/09/09 10:58:00 Intrado Digital Media
BASEL, Switzerland and NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE ® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis. The FDA set a target action date of May 6, 2022 for this sNDA under the Prescription Drug User Fee Act (PDUFA).
Myovant Sciences to Participate in the 2021 Baird Global Healthcare Conference 2021/09/01 12:30:00 Intrado Digital Media
BASEL, Switzerland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the 2021 Baird Global Healthcare Conference on September 15, 2021. Company management will participate in a fireside chat at 2:35 p.m. Eastern Time in addition to participating in small group investor meetings.
Heavy Menstrual Bleeding (HMB) Market Amazing Demand 3X Revenues by 2021-2028 with ObsEva, AbbVie, Myovant Sciences, Bayer, Enteris BioPharma, Ferring Pharmaceuticals 2021/08/30 12:17:51 OpenPR
Heavy menstrual bleeding (HMB) is one of the most common gynecological disorders affecting women of reproductive age. It is subjectively defined as heavy cyclical menstrual bleeding occurring over several consecutive cycles. As observed, it is a total blood loss of
Myovant Sciences Appoints Uneek Mehra as Chief Financial and Business Officer 2021/08/12 20:01:00 Intrado Digital Media
BASEL, Switzerland, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and men, today announced the appointment of Uneek Mehra as Chief Financial and Business Officer of Myovant Sciences, Inc. Mr. Mehra will succeed Frank Karbe, who has decided to pursue other opportunities and will serve in an advisory capacity to support Mr. Mehras transition. Beginning September 7, 2021, Mr. Mehra will lead Myovants finance, alliance partnerships, and business development functions and will be a member of Myovants Executive Committee, reporting to Dave Marek, Myovants Chief Executive Officer.
Latest Report on Female Infertility Market Report- Growth Opportunity Analysis and Forecasts | Ferring International, Myovant Sciences, ObsEva 2021/07/06 12:30:38 Jumbo News
The research reports on Female Infertility Market report gives detailed overview of factors that affect global business scope. Female Infertility Market report shows the latest market insights with upcoming trends and breakdowns of products and services. This report provides statistics on the market situation, size, regions and growth factors. Female Infertility Market report contains emerging players analyze 
Top Stock Picks for the Day: The Simply Good Foods Company (NASDAQ:SMPL), Myovant Sciences Ltd. (NYSE:MYOV) 2021/06/23 22:24:39 Stock Equity
The Simply Good Foods Company (SMPL) with the stream of -0.71% also noticed, India Myovant Sciences Ltd. (MYOV) encountered a rapid change of 0.88% in the last hour of Wednesdays The post Top Stock Picks for the Day: The Simply Good Foods Company (NASDAQ:SMPL), Myovant Sciences Ltd. (NYSE:MYOV) appeared first on Stocks Equity .
Analysts Have Conflicting Sentiments on These Healthcare Companies: Constellation Pharmaceuticals (CNST), Myovant Sciences (MYOV) and Surgalign Holdings (SRGA) 2021/06/08 09:01:26 Smarter Analyst
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Constellation Pharmaceuticals (CNST), Myovant Sciences (MYOV) and Surgalign The post Analysts Have Conflicting Sentiments on These Healthcare Companies: Constellation Pharmaceuticals (CNST), Myovant Sciences (MYOV) and Surgalign Holdings (SRGA) appeared first on Smarter Analyst .
Pfizer Consensus Indicates Potential 9.9% Upside 2021/06/04 12:14:18 DirectorsTalk
Pfizer found using ticker (PFE) have now 19 analysts covering the stock. The analyst consensus points to a rating of ''Hold''. The target price ranges between 53 and 36 with the average target price sitting at 42.62. Now with the previous closing price of 38.79 this would imply there is a potential upside of 9.9%. There is a 50 day moving average of 39.2 and the 200 day moving average is 37.13. The company has a market cap of $217,381m. Visit the company website at: /> [stock_market_widget type="chart" symbol="PFE" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.
Robert W. Baird Stick to Their Buy Rating for Myovant Sciences By Investing.com 2021/03/25 14:07:52 Investing.com
Robert W. Baird Stick to Their Buy Rating for Myovant Sciences
U.S. Uterine Fibroid Treatment Market | Blue Endo, Boston Scientific Corporation, CooperSurgical, Inc., KARL STORZ SE & Co. KG, Myovant Sciences (Sumitovant Biopharma Ltd.), Halt Medical, Inc., LiNA Medical USA, Merit Medical Systems 2021/03/23 05:59:29 OpenPR
U.S. Uterine Fibroid Treatment Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth in excessive detail. As a part of competitive analysis, the analysis study includes thorough company identification of leading
The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout 2021/02/18 13:14:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Advaxis, Inc. (NASDAQ: ADXS ) Angion Biomedica Corp (NASDAQ: ANGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avanos Medical Inc (NYSE: AVNS ) Bausch Health Companies Inc (NYSE: BHC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bioatla Inc (NASDAQ: BCAB ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Chimerix Inc (NASDAQ: CMRX ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Endo International PLC (NASDAQ: ENDP ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Lucira Health Inc (NASDAQ: LHDX ) Nektar Therapeutics (NASDAQ: NKTR ) (announced a $150-million investment by SFJ Pharma for the Phase 2/3 registrational clinical study of BEMPEG plus Keytruda in patients with head and neck cancer) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) (reacted to initiation of coverage by H.C.
Earnings Scheduled For February 11, 2021 2021/02/11 08:51:42 Benzinga
Companies Reporting Before The Bell • Bluerock Residential Growth REIT, Inc. Class A Common Stock (AMEX: BRG ) is expected to report quarterly loss at $0.55 per share on revenue of $54.86 million. • AllianceBernstein Holding (NYSE: AB ) is expected to report quarterly earnings at $0.81 per share on revenue of $805.56 million. • Applied Genetic (NASDAQ: AGTC ) is likely to report earnings for its second quarter. • Alnylam Pharmaceuticals (NASDAQ: ALNY ) is projected to report quarterly loss at $1.76 per share on revenue of $146.07 million. • Alithya Group (NASDAQ: ALYA ) is expected to report earnings for its third quarter. • AstraZeneca (NASDAQ: AZN ) is likely to report quarterly earnings at $0.68 per share on revenue of $6.97 billion. • Coca-Cola European (NYSE: CCEP ) is expected to report earnings for its fourth quarter. • Cohu (NASDAQ: COHU ) is expected to report quarterly earnings at $0.61 per share on revenue of $197.76 million. • CSP (NASDAQ: CSPI ) is estimated to report earnings for its first quarter.
Myovant Sciences (MYOV) to Release Quarterly Earnings on Thursday 2021/02/09 08:42:41 Transcript Daily
Myovant Sciences (NYSE:MYOV) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, February 11th. Analysts expect the company to announce earnings of ($0.89) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link. Myovant Sciences (NYSE:MYOV) last issued its […]
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 MYOVANT SCIENCES MYOV ）